全氟丁烷增强超声造影在肝内胆管癌中的应用:影像特征与肝脏背景及肿瘤大小的相关性
这项两中心回顾性研究纳入85个病理确诊的肝内胆管癌病灶,术前行Sonazoid超声造影(0.0165 mL/kg)。按肝脏背景和肿瘤大小分组后发现,肝纤维化或肝硬化背景及≤30 mm的病灶更常见动脉期非环状增强和相对延迟的廓清,Kupffer期所有病灶均呈明显廓清伴边界清晰。LR-M标准在高危人群中准确率为100%。
要点
- 肝纤维化或肝硬化背景的肝内胆管癌更常见动脉期非环状增强,廓清时间较正常肝背景延迟。
- ≤30 mm的肝内胆管癌较更大病灶更常见动脉期非环状增强,廓清时间相对延迟。
- Kupffer期所有肝内胆管癌均呈明显廓清并伴边界清晰,不受肝脏背景和肿瘤大小影响。
核心结论
- Sonazoid超声造影下肝内胆管癌的特征随肝脏背景和肿瘤大小而不同,肝纤维化或肝硬化背景及≤30 mm病灶更常见动脉期非环状增强和相对延迟的廓清。
研究设计与样本
- 两中心回顾性分析,纳入2019年2月至2022年7月共85个病理确诊的肝内胆管癌病灶,术前或活检前接受Sonazoid超声造影,剂量0.0165 mL/kg,前70秒连续成像,随后每15-20秒间歇扫描持续5分钟,8分钟延迟后采集Kupffer期。
关键影像表现/征象
- 肝纤维化或肝硬化背景的肝内胆管癌较正常肝背景更常见动脉期非环状增强(p=0.022)。
- 肝纤维化或肝硬化背景的肝内胆管癌廓清时间较正常肝背景延迟(39.9±8.5秒 vs 39.7±13.0秒 vs 28.1±5.6秒,p<0.001)。
- ≤30 mm的肝内胆管癌较更大病灶更常见动脉期非环状增强(p=0.003),廓清时间相对延迟(41.3±12.5秒,p=0.046)。
- Kupffer期所有肝内胆管癌均呈明显廓清并伴边界清晰,不受肝脏背景和肿瘤大小影响。
诊断标准与关键数值
- 基于超声造影肝脏影像报告和数据系统,LR-M标准在高危人群中的诊断准确率为100%。
临床应用与阅片要点
- 阅片时需结合肝脏背景(正常肝、纤维化、肝硬化)和肿瘤大小(≤30 mm、31-50 mm、>50 mm)评估肝内胆管癌的动脉期增强模式和廓清时间。
- Kupffer期所有肝内胆管癌均表现为明显廓清和边界清晰,可作为识别病灶的参考征象。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate Sonazoid contrast-enhanced ultrasound (CEUS) features of intrahepatic cholangiocarcinoma (ICC) based on liver backgrounds and tumor sizes.
METHODS: A retrospective analysis was conducted on patients with histopathologically diagnosed ICC at two centers. Patients underwent Sonazoid CEUS examination at a dose of 0.0165 mL/kg before surgery or biopsy. Continuous imaging was recorded for the first 70 s, followed by intermittent scanning every 15-20 s for 5 min, with a Kupffer phase captured after an 8-min delay. Patients were categorized by liver backgrounds and tumor sizes. Two ultrasound experts evaluated the enhancement patterns of ICCAs during the arterial, portal, delayed, and Kupffer phases according to current guidelines.
RESULTS: From February 2019 to July 2022, a total of 85 ICC lesions were included. ICCs were categorized into normal liver (n = 24), chronic liver disease with fibrosis (n = 40), and cirrhosis (n = 21) groups based on different liver backgrounds, and into groups measuring ≤30 mm (n = 22), 31-50 mm (n = 32), and >50 mm (n = 31) based on tumor sizes. Most ICCs in liver fibrosis or liver cirrhosis tended to show non-rim enhancement in arterial phase (p = 0.022) and relatively later washout (39.9 ± 8.5 s vs. 39.7 ± 13.0 s) compared with those on a normal liver background (28.1 ± 5.6 s) (p < 0.001). Based on CEUS Liver Imaging Reporting and Data System, the diagnostic performance of LR-M criteria showed an accuracy of 100% in our high-risk populations. ICCs of ≤30 mm more commonly showed non-rim enhancement in arterial phase (p = 0.003) and relatively later washout (41.3 ± 12.5 s) compared with larger ICCs (p = 0.046). In the Kupffer phase, all ICCs showed marked washout with sharp margin delineation on Sonazoid CEUS, regardless of liver backgrounds and tumor sizes.
CONCLUSION: Sonazoid CEUS features of ICCs differ according to different liver backgrounds and tumor sizes. Arterial phase non-rim enhancement and relatively later washout were more commonly observed in ICCs on liver fibrosis or cirrhosis background or smaller ICCs (≤30 mm).
引用
- Wei L, Kang HJ, Huang YL, et al. Perfluorobutane-Enhanced CEUS in Intrahepatic Cholangiocarcinoma: Correlating Imaging Features With Liver Backgrounds and Tumor Sizes. Ultrasound Med Biol. 2024. PMID: 39424496. doi:10.1016/j.ultrasmedbio.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。